Nature Reviews Endocrinology

Article	Citations
COVID-19 and diabetes mellitus: from pathophysiology to clinical management	619
Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure	429
Obesity and impaired metabolic health in patients with COVID-19	427
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19	316
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic	276
Exerkines in health, resilience and disease	275
Endocrine and metabolic link to coronavirus infection	254
Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)	249
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment	238
The role of sugar-sweetened beverages in the global epidemics of obesity and chronic diseases	237
Mitochondrial and metabolic dysfunction in ageing and age-related diseases	236
The burden and risks of emerging complications of diabetes mellitus	227
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus	218
Current understanding of the molecular and cellular pathology of diabetic retinopathy	214
Diet and exercise in the prevention and treatment of type 2 diabetes mellitus	209
Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics	199
Type 2 diabetes mellitus in older adults: clinical considerations and management	188
The health effects of vitamin D supplementation: evidence from human studies	182
Tracking placental development in health and disease	172
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus	167
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy	164
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus	162
GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease	161
Autophagy in metabolic disease and ageing	160
Endocrine toxicities of immune checkpoint inhibitors	160

Current practice in patients with differentiated thyroid cancer	150
Sexual dimorphism in cardiometabolic health: the role of adipose tissue, muscle and liver	147
Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer	146
Nearly a decade on — trends, risk factors and policy implications in global obesity	139
International consensus on the diagnosis and management of dumping syndrome	126
Will the COVID-19 pandemic worsen the obesity epidemic?	124
Environmental factors in declining human fertility	120
Metabolic regulation of kisspeptin — the link between energy balance and reproduction	113
Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation	112
Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus	106
Creatine metabolism: energy homeostasis, immunity and cancer biology	103
Clinical application of intermittent fasting for weight loss: progress and future directions	102
Exercise adaptations: molecular mechanisms and potential targets for therapeutic benefit	98
Paracetamol use during pregnancy — a call for precautionary action	92
The role of insufficient sleep and circadian misalignment in obesity	87
New insights into KATP channel gene mutations and neonatal diabetes mellitus	86
Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD	86
Metabolic pathways in obesity-related breast cancer	84
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy	84
The evolving view of thermogenic adipocytes — ontogeny, niche and function	79
International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers	76
Macrophage functional diversity in NAFLD — more than inflammation	75
Epigenetic inheritance of polycystic ovary syndrome — challenges and opportunities for treatment	74
Tuning fatty acid oxidation in skeletal muscle with dietary fat and exercise	72
The importance of the RET gene in thyroid cancer and therapeutic implications	71
Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis	70
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus	69
Novel therapies with precision mechanisms for type 2 diabetes mellitus	69
Brain insulin signalling in metabolic homeostasis and disease	68
Understanding the ever-changing incidence of thyroid cancer	67
Pathogenesis and treatment of primary aldosteronism	65
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations	64
Clinical aspects of multiple endocrine neoplasia type 1	64
The physiological role of β-cell heterogeneity in pancreatic islet function	61
Metformin: update on mechanisms of action and repurposing potential	60
Functions of galanin, spexin and kisspeptin in metabolism, mood and behaviour	60
Cellular and molecular features of EDC exposure: consequences for the GnRH network	60
Aggressive pituitary tumours and pituitary carcinomas	59
Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions	59
Adaptive immune cells shape obesity-associated type 2 diabetes mellitus and less prominent comorbidities	56
Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus	55
Primary hypothyroidism and quality of life	55
Lipid droplet biogenesis and functions in health and disease	52
Targeting lipid GPCRs to treat type 2 diabetes mellitus — progress and challenges	51
Assessment and treatment of thyroid disorders in pregnancy and the postpartum period	50
Managing fragility fractures during the COVID-19 pandemic	49
One hundred years of insulin therapy	49
Hormonal regulation of biomineralization	48
Metabolic disorders, COVID-19 and vaccine-breakthrough infections	48
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies	48

The role of biomineralization in disorders of skeletal development and tooth formation	48
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1	47
Metabolic implications of pancreatic fat accumulation	47
The role of stress kinases in metabolic disease	45
Uterine bleeding: how understanding endometrial physiology underpins menstrual health	44
Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease	42
Optoacoustic imaging in endocrinology and metabolism	42
Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia	42
Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine	41
The role of iron in host–microbiota crosstalk and its effects on systemic glucose metabolism	40
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia	40
Global accessibility of therapeutics for diabetes mellitus	39
Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis	39
The gut microbiota in obesity and weight management: microbes as friends or foe?	39
The multiple roles of life stress in metabolic disorders	39
The trials and tribulations of determining HbA1c targets for diabetes mellitus	38
Hormonal regulation of mammary gland development and lactation	38
Treating menopause — MHT and beyond	38
Management challenges and therapeutic advances in congenital adrenal hyperplasia	37
Multifaceted actions of melanin-concentrating hormone on mammalian energy homeostasis	37
Unravelling the role of epigenetics in reproductive adaptations to early-life environment	37
Multikinase inhibitors in thyroid cancer: timing of targeted therapy	37
Long COVID — metabolic risk factors and novel therapeutic management	36
Epigenetics of type 2 diabetes mellitus and weight change — a tool for precision medicine?	34
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits	34
The role of regulated necrosis in endocrine diseases	34
A global view of hypertensive disorders and diabetes mellitus during pregnancy	33
Advances in differential diagnosis and management of growth hormone deficiency in children	32
Adrenal cortex renewal in health and disease	31
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement	31
Modelling metabolic diseases and drug response using stem cells and organoids	29
Primary aldosteronism — a multidimensional syndrome	29
Intermuscular adipose tissue in metabolic disease	28
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases	28
Challenges in the care of transgender and gender-diverse youth: an endocrinologist’s view	27
Skeletal and extraskeletal disorders of biomineralization	26
Exercise in adults with type 1 diabetes mellitus	25
The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects	25
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice	24
The importance of metabolic dysfunction in polycystic ovary syndrome	24
Potential gut–brain mechanisms behind adverse mental health outcomes of bariatric surgery	24
SGLT2 inhibitors in people with and without T2DM	23
Machine intelligence in non-invasive endocrine cancer diagnostics	23
The interplay between diabetes mellitus and menopause: clinical implications	23
Insights into non-classic and emerging causes of hypopituitarism	22
COVID-19 alters thinking and management in metabolic diseases	21
Consensus Statement on the definition and classification of metabolic hyperferritinaemia	21
Revisiting the role of inflammation in the loss of pancreatic β-cells in T1DM	20
Immune dysfunction in developmental programming of type 2 diabetes mellitus	20
Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities	19
Who would have thought — myokines two decades on	19
X chromosome agents of sexual differentiation	19
Strategies for modelling endometrial diseases	19
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation	18
Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia	18
Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease	18
Exosomes as novel biomarkers in metabolic disease and obesity-related cancers	17
Diagnostic and therapeutic advances in neuroendocrine tumours	17
Severe COVID-19 outcomes — the role of physical activity	17
Heterogeneity and endotypes in type 1 diabetes mellitus	17
Is there a role for the adrenal glands in long COVID?	17
Towards a better understanding of diabetes mellitus using organoid models	16
High resolution 3D structures of mineralized tissues in health and disease	16
The G protein-coupled oestrogen receptor GPER in health and disease: an update	16
Lactate as a major myokine and exerkine	16
Long-term and sequential treatment for osteoporosis	15
Transplantation of stem cell-derived pancreatic islet cells	15
An integrated model of obesity pathogenesis that revisits causal direction	15
Metabolic determinants of tumour initiation	15
The MMP14–caveolin axis and its potential relevance for lipoedema	14
How can social jetlag affect health?	13
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer	12
SARS-CoV-2 fires up inflammation in adipose tissue	12
Adipose tissue in communication: within and without	12
Why does the immune system destroy pancreatic β-cells but not α-cells in type 1 diabetes?	11
The emerging evidence for non-skeletal health benefits of vitamin D supplementation in adults	11
Sex hormones in SARS-CoV-2 susceptibility: key players or confounders?	11
Fetoplacental oxygen homeostasis in pregnancies with maternal diabetes mellitus and obesity	11
Improving clinical outcomes through attention to sex and hormones in research	10
The role of ChREBP in carbohydrate sensing and NAFLD development	10

Paracetamol use in pregnancy — caution over causal inference from available data	10
A spectacular year for islet and stem cell transplantation	10
Metabolism and exercise: the skeletal muscle clock takes centre stage	10
Programming of metabolism by adipokines during development	10
The manifold roles of protein S-nitrosylation in the life of insulin	10
Progress in islet transplantation is more important than ever	10
Surufatinib — a novel oral agent for neuroendocrine tumours	10